Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Jazz Pharmaceuticals
With
In Phase 1 of the study, patients were to receive 375 or 625 mg ONC201 once every week in combination with dexamethasone using a 3+3 dose escalation design to evaluate up to 625 mg ONC201 weekly with 20 mg dexamethasone. In Phase 2 of the study, patients were to receive 625 mg ONC201 once every week. Dexamethasone was to be administered at a dose determined in Phase 1. A treatment cycle was defined as 3 weeks. The dose-limiting toxicity window was defined as the first 3 weeks of treatment (i.e., 1 cycle). Patients may have continued treatment with ONC201 until disease progression, occurrence of an unacceptable adverse event, intercurrent illness or changes in the patient's condition rendered the patient unacceptable to continue, patient decision to withdraw from the study, or discontinuation of the study by the Sponsor. Assessments of tumor response were conducted using the International Myeloma Working Group response criteria. Safety was assessed through the reporting of adverse events, measurement of vital signs, electrocardiograms, and clinical laboratory results. Before the study was terminated, a total of 17 patients were enrolled and treated with ONC201: 2 patients received 375 mg ONC201 and 15 patients received 625 mg ONC201.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
